Peptide News Digest

#Heidi-Overton

2 stories

Regulatory · View digest

Trump Administration Formally Nominates Dr. Heidi Overton as FDA Commissioner; PCAC Peptide Rulemaking Pipeline Now Runs Through Incoming Regime

President Trump announced Wednesday August 19, 2026 the formal nomination of Dr. Heidi Overton, a physician who currently works as deputy assistant to the president for domestic policy and formerly chief policy officer at America First Policy Institute, to serve as the next commissioner of the U.S. Food and Drug Administration. If confirmed by the U.S. Senate, Overton would take over from Kyle Diamantas (JD), who has served as acting commissioner since May 2026 following the departure of Marty Makary. Overton holds an MD from the University of New Mexico and a PhD in clinical investigation from Johns Hopkins Bloomberg School of Public Health, and served in the first Trump administration in the Office of American Innovation and Domestic Policy Council. She is Trump's third choice for the position after former Rep. Brad Wenstrup (R-Ohio) and acting Commissioner Diamantas both declined. The nomination matters for peptide-industry readers because the FDA rulemaking to translate the July 23-24 PCAC 6-peptide 503A recommendation (BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon) into a proposed rule (and eventually a final rule) will run through Overton's tenure if she is confirmed; the February 2027 PCAC meeting on cathelicidin, GHK-Cu, dihexa acetate, melanotan II, and PEG-MGF falls entirely within the window.

Regulatory · View digest

White House Reviewing Three Finalists to Lead the FDA (STAT News Reporting, July 8-9): Heidi Overton (Current White House Policy Adviser), Jeffrey Vacirca (Oncologist and Health-System Executive), and Stephen Ferrara (Department of Defense Health Official) Emerged as the Shortlist Following the March 2026 Departure of Prior Commissioner; Peptide Policy Trajectory Runs Through Whichever Nominee Advances Given PCAC July 23-24 Vote and Ongoing Compounding-Rule Environment

STAT News' Pharmalot newsletter reported Wednesday-Thursday July 8-9, 2026 that the White House is reviewing three finalists to lead the FDA following the departure of the prior commissioner earlier in 2026: Heidi Overton, a policy adviser in the White House itself; Jeffrey Vacirca, an oncologist and health-system executive; and Stephen Ferrara, a health official at the Department of Defense. Axios first surfaced the shortlist on June 26; the July 8-9 STAT reporting confirmed the trio is under active White House review with a decision expected in the coming weeks. The peptide policy trajectory tracks through whichever nominee advances. FDA career-staff briefing documents released June 29-30 concluded all seven PCAC peptides have insufficient evidence for 503A eligibility, while HHS Secretary RFK Jr.'s public push points the other direction; the incoming commissioner will inherit an agency-vs-secretary tension around peptide compounding as the July 23-24 PCAC vote lands. The nominee will also inherit the pending Novo Nordisk-Vivani semaglutide-implant evaluation agreement, the Sandoz generic-tirzepatide ANDA acceptance from June 29, and the ongoing 503B GLP-1 exclusion rulemaking.